Still Flaring? Skyrizi vs Stelara for Crohn's Remission: New Medical Data

If you're still flaring despite treatment, you're not alone. Crohn's disease can be unpredictable, and finding the right biologic can take time. Two of the most talked-about options today are Skyrizi (risankizumab) and Stelara (ustekinumab). Both are advanced biologic therapies, but they work in slightly different ways—and newer data is helping clarify how they compare.

Here's what current medical evidence says about Skyrizi vs Stelara for Crohn's remission, explained in clear, practical terms.

---

How Do Skyrizi and Stelara Work?

Both medications target inflammation in the immune system, but they focus on different pathways.

Stelara (ustekinumab)

• Blocks IL-12 and IL-23, two inflammatory proteins.
• Approved for Crohn's disease since 2016.
• Given as:
  • One-time IV infusion (starter dose)
  • Followed by injections every 8 weeks (sometimes every 4 weeks if needed)

Skyrizi (risankizumab)

• Blocks IL-23 only (more targeted approach).
• Approved for Crohn's disease in 2022.
• Given as:
  • Three IV induction doses (weeks 0, 4, 8)
  • Then an on-body injector every 8 weeks

The key difference: Skyrizi is more selective, targeting only IL-23. Researchers believe this focused approach may improve remission rates while maintaining safety.

---

What Does the Latest Data Show?

When comparing Skyrizi vs Stelara for Crohn's remission, we look at three main outcomes:

1. Clinical remission (symptoms improve)
2. Endoscopic remission (healing seen on colonoscopy)
3. Long-term maintenance of remission

1. Clinical Remission Rates

In large clinical trials:

Skyrizi

• Induction remission rates around 40–45% at 12 weeks (in moderate to severe Crohn's)
• Higher rates in patients who had failed anti-TNF therapies
• Maintenance remission at 52 weeks: approximately 52–55%

Stelara

• Induction remission rates around 34–40%
• Maintenance remission at 44–52 weeks: approximately 45–53%

What this means:
Both drugs are effective. However, newer head-to-head trial data (SEQUENCE trial) showed that Skyrizi was superior to Stelara in achieving endoscopic remission and slightly better in overall disease control in patients who previously failed anti-TNF therapy.

---

2. Endoscopic Healing (Mucosal Healing)

This is critical. Symptom control matters—but true remission includes healing inside the bowel.

In direct comparison studies:

• Skyrizi showed significantly higher endoscopic remission rates
• Greater reduction in ulceration and inflammatory lesions
• Stronger evidence of deep remission

Why this matters:

• Endoscopic healing reduces hospitalization risk
• Lowers risk of surgery
• May reduce long-term complications

This is where Skyrizi appears to have a measurable edge.

---

3. Durability and Long-Term Control

Both medications show:

• Sustained remission beyond one year
• Continued response in patients who previously failed biologics
• Stable safety profiles

However:

• Dose escalation is sometimes required with Stelara (moving to every 4 weeks)
• Skyrizi's fixed maintenance schedule has shown consistent durability so far

Long-term real-world data for Stelara is stronger simply because it has been available longer. Skyrizi's long-term data is growing and promising.

---

Safety Comparison

When evaluating Skyrizi vs Stelara for Crohn's remission, safety is just as important as effectiveness.

Common Side Effects (Both Medications)

• Upper respiratory infections
• Headache
• Fatigue
• Injection site reactions

Serious Risks (Uncommon but Possible)

• Serious infections
• Allergic reactions
• Rare immune-related complications

Key differences:

• Neither medication appears to significantly increase overall cancer risk based on current data.
• Both have lower infection risk compared to anti-TNF biologics.
• Skyrizi's more targeted mechanism may theoretically reduce certain immune suppression risks, though long-term data is still accumulating.

Overall, both medications are considered safe and well tolerated for most patients.

---

Who Might Benefit More from Skyrizi?

Skyrizi may be especially helpful for:

• Patients who failed anti-TNF therapy
• Those who did not achieve deep remission on Stelara
• Individuals needing stronger endoscopic healing
• Patients preferring an 8-week fixed dosing schedule

---

Who Might Prefer Stelara?

Stelara may be a good fit if:

• You've been stable on it and responding well
• You have coexisting psoriasis or psoriatic arthritis (dual benefit)
• You prefer a medication with longer real-world history

Switching medications should always be based on symptoms, imaging, lab markers, and discussion with your GI specialist.

---

What If You're Still Flaring?

Persistent symptoms may include:

• Abdominal pain
• Diarrhea
• Blood in stool
• Fatigue
• Weight loss
• Fever

If you're experiencing any of these symptoms and want to better understand whether they could be related to Crohn's Disease, a free AI-powered symptom checker can help you document and organize what you're feeling before your next doctor's appointment.

However, this is not a substitute for medical care.

---

The Big Picture: Which Is Better?

When directly comparing Skyrizi vs Stelara for Crohn's remission, current evidence suggests:

• Both are effective.
• Skyrizi shows higher rates of endoscopic remission.
• Clinical remission rates are similar, with a slight edge toward Skyrizi in newer trials.
• Safety profiles are comparable.
• Stelara has longer long-term real-world data.

In simple terms:

• If you're not achieving deep remission on Stelara, Skyrizi may offer stronger disease control.
• If you're doing well on Stelara, there may be no reason to switch.

Treatment decisions are personal and depend on:

• Prior biologic exposure
• Disease severity
• Complications (fistulas, strictures)
• Lab markers (CRP, fecal calprotectin)
• Colonoscopy findings
• Insurance coverage

---

Important: When to Seek Urgent Care

Crohn's disease can sometimes become serious quickly. Seek immediate medical care if you experience:

• Severe abdominal pain
• Persistent vomiting
• High fever
• Signs of bowel obstruction
• Heavy rectal bleeding
• Dehydration

These can be life-threatening if untreated.

---

Final Thoughts

The comparison of Skyrizi vs Stelara for Crohn's remission is no longer theoretical. We now have direct clinical data showing that Skyrizi may offer stronger endoscopic healing, especially in patients who previously failed anti-TNF therapy. However, both medications are strong options and have helped many people achieve meaningful remission.

If you're still flaring, don't ignore it. Ongoing inflammation can lead to complications over time.

Speak to a gastroenterologist about:

• Whether you're in true remission
• Whether imaging or colonoscopy is needed
• If switching biologics makes sense
• Monitoring inflammation markers regularly

Most importantly, do not make medication changes without medical supervision. Crohn's disease requires careful, individualized treatment.

Remission is possible—but it often requires the right therapy, close follow-up, and open communication with your doctor.